effect overlay
activetrials
Dementia
Dementia
SLT for Vascular Dementia

A Multicentre, Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effectiveness and Safety of Sailuotong (SLT), a Standardised Herbal Medicine Formula in Patients with Vascular Dementia and Alzheimer's Disease with Cerebrovascular Disease
 

HREC: 2018.225
Principal Investigator: A/Prof Nawaf Yassi
Coordinator contact: Sophie Robinson
Funding: Non-Commercial
Dementia
Dementia
3D

Deferiprone to Delay Dementia (The 3D Study): a clinical proof of cencept study
 

HREC: 2017.172
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial
Dementia
Dementia
Anavex 003

A Phase IIa Study of ANAVEX2-73 Adaptive Trial Design with repeated doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 52 week Open Label Follow-Up period 
 

HREC: 2016.097
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial
Placeholder
Brain Tumour/Neurosurgery
Brain cancer survivorship - Phase 2

Responding to need: technology-enhanced brain cancer survivorship – Phase 2
 

HREC: 2022.264
Principal Investigator: Prof Kate Drummond
Coordinator contact: Dr Verena Schadewaldt
Funding: Non-Commercial
Placeholder
Brain Tumour/Neurosurgery
BrainPOP: The Brain Perioperative Platform

An adaptive, multi-domain platform of comprehensive translational and feasibility research to study the biology of brain and other central nervous system (CNS) cancers
 

HREC: 2022.220
Principal Investigator: Prof Kate Drummond
Coordinator contact: Dr Jordan Jones
Funding: Non-Commercial